$MDWD News
Last published 1d ago
- 1d agoMDWDMediWound Q3 2026 Earnings Call - MEDIWOUND LTDEarnings Call TranscriptsGood day and welcome to MediWool's 3rd Quarter 2026 Earnings Call, as all participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by
- 1d agoMDWDMediWound Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Third Quarter Revenue of...
- 1w agoMDWDMediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary SharesGlobeNewswireMediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ:MDWD) ("MediWound"), a global leader in
- 1w agoMDWDMediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary SharesGlobeNewswireMediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) — MediWound Ltd....
- 1w agoMDWDMediWound Announces $15 Million Bought Deal Offering of Ordinary SharesGlobeNewswireMediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ:MDWD) ("MediWound"), a global leader in next-generation
- 2w agoMDWDMediWound to Report Third Quarter 2026 Financial ResultsGlobeNewswireMediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a
- 2mo agoMDWDIndependent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without ModificationGlobeNewswireIndependent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain
- 2mo agoMDWDMediWound to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireMediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for
- 3mo agoMDWDMediWound Q2 2026 Earnings Call - MEDIWOUND LTDEarnings Call TranscriptsGood day, and welcome to the MediWUN Second Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key
- 3mo agoMDWDMediWound Q2 2026 Earnings Call - MEDIWOUND LTDEarnings Call TranscriptsGood day, and welcome to the MediWUN Second Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key
- 3mo agoMDWDMediWound Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second
- 3mo agoMDWDMediWound to Report Second Quarter 2026 Financial ResultsGlobeNewswireMediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global
- 5mo agoMDWDMediWound Q1 2026 Earnings CallMEDIWOUND LTDEarnings Call TranscriptsGood day, and welcome to the Meadowoon First Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key
- 5mo agoMDLNMDWDMediWound Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance
- 6mo agoMDWDMediWound to Report First Quarter 2026 Financial ResultsGlobeNewswireMediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global
- 7mo agoMDWDNewly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound DebridementGlobeNewswireNewly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active
- 7mo agoMDWDMediWound to Present New EscharEx® Data at Leading Wound Care ConferencesGlobeNewswireMediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support ongoing
- 7mo agoMDWDVCELMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionGlobeNewswireMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics
- 8mo agoMDWDMediWound Files Annual Report on Form 20-FGlobeNewswireMediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has filed
- 8mo agoMDWDMediWound Q4 and Full Year 2025 Earnings CallMEDIWOUND LTDEarnings Call TranscriptsGood day, everyone, and welcome to MediWound's fourth quarter and full year 2025 earnings call. Today's conference call is being recorded. At this time, I would like to turn the conference call over to Gaia Seamus of Lif
- 8mo agoMDWDMediWound Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireEscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in cash at
- 8mo agoMDWDMediWound to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireMediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd.
- 8mo agoMDWDMediWound to Present at Upcoming Investor ConferencesGlobeNewswireMediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that
- 10mo agoMDWDMediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare ConferenceGlobeNewswireMediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers
- 11mo agoMDWDMediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast InjuriesGlobeNewswireMediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes embedded
- 11mo agoMDWDMediWound Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireOngoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 Balance
- 1y agoMDWDMediWound to Report Third Quarter 2025 Financial ResultsGlobeNewswireMediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (NASDAQ:MDWD) (the
- 1y agoMDWDMediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®GlobeNewswireMediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® Newly commissioned facility marks a significant development toward a sixfold production capacity increase ahead of
- 1y agoMDWDMediWound Announces $30 Million Registered Direct Offering of Ordinary SharesGlobeNewswire
- 1y agoMDWDMediWound Expands Global Reach with Marketing Approval of NexoBrid® in AustraliaGlobeNewswire
- 1y agoMDWDMediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressGlobeNewswireMediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in
- 1y agoMDWDMediWound to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireYAVNE, Israel, August 20, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a
- 1y agoMDWDMediWound Ltd. (MDWD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMDWDMediWound Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireVALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic
- 1y agoMDWDMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg UlcersGlobeNewswireMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides
- 1y agoMDWDMediWound to Report Second Quarter 2025 Financial ResultsGlobeNewswireMediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global
- 1y agoMDWDMediWound Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireVALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4
- 1y agoMDWDMediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg UlcersGlobeNewswireYAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc
- 1y agoMDWDMediWound to Report First Quarter 2025 Financial ResultsGlobeNewswireYAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the
- 1y agoMDWDMediWound to Present New EscharEx® Data at Leading Wound Care ConferencesGlobeNewswirePresentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs
- 1y agoMDWDMediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireInitiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24
- 1y agoMDWDMediWound to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireYAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results
- 1y agoMDWDMediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn CareGlobeNewswireFindings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25,
- 1y agoMDWDMediWound to Present at the 45th Annual TD Cowen Health Care ConferenceGlobeNewswireYAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will
- 1y agoMDWDMediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg UlcersGlobeNewswirePhase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026
- 1y agoMDWDMediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireYAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will
- 1y agoMDWDMediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025GlobeNewswireYAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader
- 1y agoMDWDMediWound Ltd. (MDWD) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMDWDMediWound Reports Third Quarter 2024 Financial Results and Provides Company UpdateGlobeNewswireEscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding
- 2y agoMDWDMediWound to Report Third Quarter 2024 Financial ResultsGlobeNewswireYAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results